There are 2789 resources available
453P - Routine DPYD mutation testing for patients receiving fluoropyrimidines for gastrointestinal (GI) cancers: Real world experience in a tertiary UK oncology centre
Presenter: David Lau
Session: ePoster Display
454P - CCR5/CCL5 gene expression in colorectal cancer (CRC): Comprehensive profiling and clinical value
Presenter: Francesca Battaglin
Session: ePoster Display
455P - Concordance of baseline RAS mutational status (ms) between tissue and cell-free DNA (cfDNA) and association with overall response rate (ORR) in first-line (1L) metastatic colorectal cancer (mCRC) patients (pts): PERSEIDA study (cohort 2) (NCT02792478)
Presenter: Manuel Valladares-Ayerbes
Session: ePoster Display
456P - Prognostic and predictive value of tumor-infiltrating lymphocytes in combination with systemic inflammatory markers in colon cancer
Presenter: Safa Can Efil
Session: ePoster Display
457P - Circulating tumor DNA (ctDNA) from patients (pts) with advanced colorectal cancer (CRC) is enriched for EGFR extracellular domain (ECD) mutations
Presenter: Sabine Tejpar
Session: ePoster Display
505TiP - REGINA: A phase II trial of neoadjuvant regorafenib (rego) in combination with nivolumab (nivo) and short-course radiotherapy (SCRT) in intermediate-risk, stage II-III rectal cancer (RC)
Presenter: Giacomo Bregni
Session: ePoster Display
506TiP - Pembrolizumab plus lenvatinib versus standard of care for previously treated metastatic colorectal cancer (mCRC): Phase III LEAP-017 study
Presenter: Takayuki Yoshino
Session: ePoster Display
507TiP - PRESERVE 1: A phase III, randomized, double-blind trial of trilaciclib versus placebo in patients receiving FOLFOXIRI/bevacizumab for metastatic colorectal cancer
Presenter: Joleen Hubbard
Session: ePoster Display
509TiP - REPROGRAM-01, a phase II study of regorafenib in combination with a multimodal metronomic chemotherapy in patients with metastatic colorectal cancer
Presenter: Elodie Klajer
Session: ePoster Display